Schedule 13G ownership disclosure

Apogee Therapeutics Inc

COMMON STOCK · CUSIP: 03770N101

Event date: 2026-02-28

Filing-level shares
6,213,827
Percent of class
11.3%
  • T. Rowe Price Investment Management, Inc.

    Shares: 6,213,827 · Class: 11.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001897612-26-000311
Form type
SCHEDULE 13G
Filer
Apogee Therapeutics, Inc.
CIK
CIK 1974640
Filed
Mar 06, 2026
Reporting period
Feb 28, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub